A combination phase I trial of peptide vaccines and Docetaxel/5'-DFUR in patients with advanced or recurrent gastric cancer

A combination phase I trial of peptide vaccines and Docetaxel/5'-DFUR in patients with advanced or recurrent gastric cancer - Phase I trial of peptide vaccines in patients with advanced or recurrent gastric cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009751

Enrollment

Registered

2013-01-11

Start date

2007-11-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastric cancer

Interventions

Dose escalation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Serious infectious disease or other severe complications (e.g. pulmonary fibrosis / interstitial pneumonia, uncontrollable diabetes); pregnancy or lactation, or trying to get pregnant; a history of drug allergy

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological effect Objective responses Overall survival	—

Countries

Japan

Contacts

Public ContactShigefumi Yoshino

Yamaguchi University Graduate School of Medicine Digestive surgery and surgical oncology

sigefumi@yamaguchi-u.ac.jp0836-22-2264

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026

A combination phase I trial of peptide vaccines and Docetaxel/5&#39;-DFUR in patients with advanced or recurrent gastric cancer